| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.8 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |